Aggressive Treatment De-Escalation Feasible in HPV-Positive Oropharyngeal Cancer?

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video highlights 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Daniel J. Ma, MD, of the Mayo Clinic in Rochester, Minnesota, discusses 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.

      Ma presented results of the study (abstract LBA-14) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

      Recent Videos
      Durvalumab Inferior to Cetuximab in Contraindicated Cisplatin HNSCC
      Durvalumab Inferior to Cetuximab in Contraindicated Cisplatin HNSCC
      Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
      Further Research May Explore Systemic Therapy Failure Following RT in NSCLC
      Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
      Data Show Increasing Systemic Therapy Use in NSCLC Radiotherapy Population
      Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
      Reflexology Program May Have Use in Integrative Breast Cancer Care
      A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
      ctDNA Data in Gynecologic Cancer RT Population May Be Hypothesis-Generating
      Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
      Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC
      ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
      ctDNA Clearance Confers Responses to Radiation in Gynecologic Malignancies
      Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
      Assessing ctDNA as a Predictor of RT Responses in Gynecologic Cancers
      Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
      Reflexology Reduces Stress/Pain, Increases Energy During Breast Cancer RT
      Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
      Evaluating Reflexology Impact on Breast Cancer RT-Related Anxiety, Pain
      Related Content
      Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

      Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

      Ariana Pelosci
      March 20th 2025
      Article

      Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.

      David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

      David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

      David J. Sher, MD, MPH
      September 15th 2017
      Podcast

      In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

      Pembrolizumab/Bevacizumab Improves Efficacy in Nasopharyngeal Carcinoma

      Pembrolizumab/Bevacizumab Improves Efficacy in Nasopharyngeal Carcinoma

      Tim Cortese
      March 2nd 2025
      Article

      Pembrolizumab and bevacizumab yielded an ORR of 58.3% vs 12.5% with pembrolizumab monotherapy in patients with platinum-resistant nasopharyngeal carcinoma.

      Support for the supplemental biologics license application is based on phase 3 KEYNOTE-689 trial data.

      Pembrolizumab Earns FDA Priority Review in Locally Advanced HNSCC

      Roman Fabbricatore
      February 25th 2025
      Article

      Support for the supplemental biologics license application is based on phase 3 KEYNOTE-689 trial data.

      Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

      Petosemtamab Combo Earns Breakthrough Therapy Status in PD-L1+ HNSCC

      Russ Conroy
      February 20th 2025
      Article

      Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

      Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.

      Cetuximab/Radiation Improves DFS in Locally Advanced SCCHN

      Russ Conroy
      February 1st 2025
      Article

      Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.